{"url_path":"/sec/pfe/8-k/2026-04-27/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/78003/0000078003-26-000044-index.html","accession_number":"0000078003-26-000044","cik":"0000078003","ticker":"PFE","issuer_name":"PFIZER INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/78003/0000078003-26-000044-index.html","primary_entity_key":"0000078003","primary_entity_name":"PFIZER INC"},"word_count":321,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders\n\n(a) The Pfizer Inc. (the \"Company\") Annual Meeting of Shareholders was held on April 23, 2026.\n\n(b) Shareholders voted on the matters set forth below.\n\n1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:\n\nNominee\n\nVotes For      \n\nVotes Against\n\nAbstentions\n\nBroker non-vote\n\nRonald E. Blaylock3,442,653,662102,600,74811,374,500941,392,137\n\nAlbert Bourla3,261,211,737272,132,57323,284,563941,392,137\n\nMortimer J. Buckley3,403,974,675141,036,93211,617,303941,392,137\n\nSusan Desmond-Hellmann3,401,932,807141,056,14713,639,956941,392,137\n\nJoseph J. Echevarria2,929,511,380612,413,50214,702,274941,392,137\n\nScott Gottlieb3,415,886,776130,394,18510,343,738941,392,137\n\nDan R. Littman3,383,769,589161,740,87211,118,449941,392,137\n\nShantanu Narayen3,313,318,763231,613,93211,695,915941,392,137\n\nSuzanne Nora Johnson3,272,936,863273,506,15110,185,896941,392,137\n\nJames Quincey3,453,778,74191,549,23611,300,933941,392,137\n\nJames C. Smith3,284,035,682261,217,69911,375,529941,392,137\n\nCyrus Taraporevala3,468,177,42376,665,72111,785,766941,392,137\n\n2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was approved based upon the following votes:\n\nVotes for approval\n4,160,827,231\n\nVotes against\n321,979,096\n\nAbstentions\n15,214,720\n\nBroker non-votes\n\nn/a\n\n3. The proposal to approve the Pfizer Inc. 2019 Stock Plan, as amended April 2026 was approved based upon the following votes:\n\nVotes for approval\n3,227,692,578\n\nVotes against\n305,428,376\n\nAbstentions\n23,507,956\n\nBroker non-votes\n941,392,137\n\n4. The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers was approved based upon the following votes:\n\nVotes for approval\n3,099,249,442\n\nVotes against\n423,935,881\n\nAbstentions\n33,443,287\n\nBroker non-votes\n941,392,137\n\n5. The shareholder proposal to Adopt Adopt An Independent Chair Policy was not approved based upon the following votes:\n\nVotes for approval\n1,015,206,372\n\nVotes against\n2,509,042,021\n\nAbstentions\n32,354,566\n\nBroker non-votes\n941,392,137\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n PFIZER INC.\n\n   \n\n   \n\nDated: April 27, 2026By:/s/ Margaret M. Madden\n\n Margaret M. Madden\n\n  Senior Vice President and Corporate Secretary\n\n  Chief Governance Counsel"}